Citi 9th Annual Biotech Conferencein
Bostonon Thursday, September 4, 2014. Management will
participate in a panel discussion entitled “Emerging Ophthalmology
Therapies: Getting 20/20 on the Drug Landscape” at 12:00 p.m. E.T.NewsMakers in the Biotech Industry Conferencein New York on
Friday, September 26, 2014. Management will present a corporate
overview at 11:00 a.m. ET.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Eleven Biotherapeutics (NASDAQ: EBIO), a biopharmaceutical company
discovering and developing protein therapeutics to treat diseases of the
eye, today announced that Abbie Celniker, Ph.D., President and Chief
Executive Officer, will participate in the following upcoming investor
conferences in September:
A live webcast of the NewsMakers in the Biotech Industry Conference can
be accessed from the Investors & Media section of Eleven’s website at www.elevenbio.com.
An archived replay of the webcast will be available on the Company’s
website for 7 days after the conference.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical
company with a proprietary protein engineering platform, called AMP-Rx,
that it applies to the discovery and development of protein therapeutics
to treat diseases of the eye. The Company’s therapeutic approach is
based on the role of cytokines in diseases of the eye, the Company’s
understanding of the structural biology of cytokines and the Company’s
ability to rationally design and engineer proteins to modulate the
effects of cytokines. Cytokines are cell signaling molecules found in
the body that can have important inflammatory effects.
Leah Monteiro, 617-714-0619
Source: Eleven Biotherapeutics